DCTD Double Nickase Plasmid (h): sc-405193-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- DCTD Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- DCTD Double Nickase Plasmid (h) and DCTD Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting DCTD. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: DCTD Antibody (F-9): sc-376659
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
DCTD Double Nickase Plasmid (h) | sc-405193-NIC | 20 µg | $410.00 | |||
DCTD Double Nickase Plasmid (h2) | sc-405193-NIC-2 | 20 µg | $410.00 |
Human DCTD encodes deoxycytidylate deaminase, a cytosolic enzyme that catalyzes the deamination of dCMP to dUMP, providing a key source of dUMP for thymidylate biosynthesis and maintaining balanced deoxynucleotide pools. Through its role in pyrimidine metabolism, DCTD supports DNA replication and repair by influencing dTTP availability and limiting replication stress. Perturbation of nucleotide homeostasis is a common feature of rapidly proliferating cells and is frequently associated with genome instability in cancer biology. DCTD therefore serves as a useful molecular node for studying metabolic control of DNA synthesis, cell-cycle progression, and nucleotide imbalance–driven stress responses.
DCTD Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the DCTD locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within DCTD. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt DCTD function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of DCTD-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.